Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study
Vor Biopharma VOR, a clinical-stage company, announced dosing the first patient in its phase I/II study of VCAR33ALLO for the treatment of relapsed/refractory acute myeloid leukemia (AML).
VCAR33ALLO is Vor Bio’s transplant donor-derived CAR-T developmental therapy. Top-line results from the VBP301 study are expected in the second half of 2024.
The company further reported extending its cash runway into the second half of 2025 through an internal review and prioritization process. Vor Bio will continue to invest in its platform and clinical programs while strategically prioritizing late-stage programs and managing employee growth to preserve cash.
In response to the news, the company’s stock gained 7.4% on Jan 18, 2024. The share price further continued the upward trajectory during after-market hours. Over the past year, shares of VOR have plunged 55.9% compared with the industry’s 13.8% decline.
Image Source: Zacks Investment Research
The company believes that the dosing of the first patient in the phase I/II VBP301 first-in-human AML study is a significant milestone achievement as it demonstrates Vor Bio’s ability to successfully manufacture VCAR33ALLO in its in-house manufacturing facility.
VCAR33ALLO follows a novel therapeutic approach and is manufactured from lymphocytes collected from the patient’s original transplant donor, generating a CAR-T cell product, which exactly matches the recipient’s engrafted blood system.
The use of healthy transplant donor cells to manufacture VCAR33ALLO allows the cell therapy to have a more stem-like phenotype. This leads to greater potential for expansion, persistence and anti-leukemia activity compared with existing autologous or allogeneic off-the-shelf products, which are derived from a patient’s own lymphocytes.
AML is the most common type of acute leukemia (blood cancer) in adults affecting 20,000 newly diagnosed patients each year in the United States. Patients diagnosed with AML face a very poor prognosis, given the fatal and aggressive nature of this blood cancer.
Vor Biopharma Inc. Price and Consensus
Vor Biopharma Inc. price-consensus-chart | Vor Biopharma Inc. Quote
Zacks Rank and Stocks to Consider
Vor Bio currently carries a Zacks Rank #3 (Hold).
Some better-ranked drug/biotech stocks worth mentioning are Puma Biotechnology, Inc. PBYI, ADMA Biologics ADMA and Acadia Pharmaceuticals ACAD. While PBYI and ADMA sport a Zacks Rank #1 (Strong Buy) each, ACAD carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 30 days, the Zacks Consensus Estimate for Puma Biotech’s 2023 earnings per share (EPS) has increased from 72 cents to 73 cents. During the same time frame, the consensus estimate for Puma Biotech’s 2024 EPS has increased from 64 cents to 69 cents. Over the past year, shares of PBYI have rallied 16.7%.
PBYI beat estimates in three of the last four quarters while missing on one occasion, delivering a four-quarter average earnings surprise of 76.55%.
In the past 30 days, the Zacks Consensus Estimate for ADMA Biologics’ 2023 loss per share has narrowed from 3 cents to 2 cents. The consensus estimate for ADMA Biologics’ 2024 EPS is pegged at 22 cents. Over the past year, shares of ADMA have risen 43.4%.
ADMA beat estimates in three of the trailing four quarters and matched in one, delivering an average earnings surprise of 63.57%.
In the past 30 days, the Zacks Consensus Estimate for Acadia’s 2023 loss per share has remained constant at 33 cents. During the same time frame, the consensus estimate for Acadia’s 2024 EPS is pegged at $1.04. Over the past year, shares of ACAD have gained 42.6%.
ACAD beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average earnings surprise of 20.69%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Puma Biotechnology, Inc. (PBYI) : Free Stock Analysis Report
ADMA Biologics Inc (ADMA) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
Vor Biopharma Inc. (VOR) : Free Stock Analysis Report
